Dr. Linden is the Athena Distinguished Professor of Breast Cancer Research and a medical oncologist specializing in breast cancer, with expertise in endocrine therapy, clinical trials, and molecular imaging. Her clinical practice at the University of Washington includes SCCA and Harborview Medical Center; she helps patients across both organizations access clinical trials and researchers develop trials. Her research is focused on novel breast cancer therapies and molecular imaging techniques. Areas of particular interest and focus include the development of FES quantitative imaging to determine which patients will benefit from endocrine therapy. She is the co-PI of EAI 142, a cooperative national trial of FES as a biomarker. In collaboration with chemistry and physics at UW she has studied the fidelity of FDG PET and experimental tracers (FES and FLT, measures of ER uptake and proliferation) as part of a collaborative U01 in the NCI's quantitative imaging network. She is working on clinical trials to determine the bioactivity of oral SERDs (selective ER down-regulators) in development by measuring pharmacodynamic imaging. The group at UW played a major role in the development of FES PET and the FDA approval of this tracer, which will lead to more precise and tolerable regimens for metastatic breast cancer. From the UW Program Project grant in molecular imaging, we have a database of FES studies and have recently analyzed patterns in male breast cancer and lobular breast cancer and changes in quantitative ER expression in patients on treatment. In addition, she is the Associate Program Director of the Medical Oncology and Hematology Fellowship Program and the Director of the Breast Cancer Program at the Fred Hutchinson Cancer Center and UW Medicine, and an Adjunct Professor of Radiology.